证券代码：002250 证券简称：联化科技 公告编号：2025-056 联化科技股份有限公司 关于受让郡泰医药20%股权并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 三、备查文件 1、郡泰医药营业执照； 2、变更（备案）信息。 特此公告。 联化科技股份有限公司董事会 二○二五年十一月二十九日 2025年10月9日，联化科技股份有限公司（以下简称"公司"）与张立清、乐 和友、董伙祥、陈川、阮建奇和张涛签订了《股权转让合同》，决定以自有资金 受让上述人员所持有的湖北郡泰医药化工有限公司（以下简称"郡泰医药"）20% 股权，受让总金额为2,500.00万元人民币（以下简称"本次受让"）。本次股权受 让完成后，公司将直接持有郡泰医药100%股权。本次受让已经公司第九届董事 会第二次会议审议批准，无需提交公司股东会审议。具体详见公司2025年10月11 日刊登于《证券时报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn）的《关 于受让控股子公司郡泰医药20%股权的公告》（公告编号：2025-044）。 二、进展情 ...

Core Insights - The company has shown significant recovery in net profit during the first three quarters of 2025, with a revenue of 4.72 billion yuan, representing an 8.25% year-on-year increase, and a non-recurring net profit of 300 million yuan, up 1504% year-on-year [1] - The company is expanding its mature pharmaceutical business while investing heavily in new development directions, including advancements in drug technology and services [2] - The agricultural protection market is beginning to recover, with the company establishing a global supply chain through its Malaysian base, which is expected to start production within 1 to 2 years [3] - The company is also investing in new energy products, with significant projects underway to enhance its production capacity in lithium-related products [3] Summary by Sections Financial Performance - In the first three quarters of 2025, the company achieved an operating income of 4.72 billion yuan, a year-on-year increase of 8.25% - The non-recurring net profit reached 300 million yuan, reflecting a substantial year-on-year growth of 1504% - The gross profit margin stood at 25.96%, an increase of 3.25 percentage points compared to the previous year [1] Pharmaceutical Business Development - The company is focusing on expanding its pharmaceutical product technology research and development, moving from traditional small molecule drugs to amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [2] - The team is enhancing early clinical project conversion for clients by providing diverse linker synthesis services necessary for developing ADC/PROTAC drugs [2] Agricultural Protection Market - The agricultural protection market is recovering from a period of excess inventory due to global supply chain disruptions from 2019 to 2022, with demand expected to rebound in the second half of 2024 [3] - The company is collaborating with multiple international agricultural/plant protection companies to drive CDMO business through technological innovation [3] - The Malaysian base is under construction and aims to support CDMO business for agricultural protection products during the patent period, with production expected to start in 1 to 2 years [3] New Energy Initiatives - The company is investing 650 million yuan in projects to produce 200,000 tons of electrolyte, 20,000 tons of LT612 (lithium hydroxide monohydrate), and other lithium-related products [3] - The planned production capacity for lithium hexafluorophosphate is set at 20,000 tons per year, while the capacity for lithium bis(fluorosulfonyl)imide is projected at 10,000 tons per year [3] - The new energy business has achieved revenue breakthroughs, primarily from sales of LiFSI and electrolyte products, while the lithium hexafluorophosphate project is still undergoing technical improvements [3]

Charles Zhuang 庄怀超 SFC CE: BTE209 微信: zhuangcharles; 电话: (852) 9748 7114; 28 Nov 2025 环球富盛理财有限公司 联化科技 Lianhe Chemical Technology (002250.SZ) 盈利能力修复，新能源板块打开未来成长空间 Profitability repair & New energy sector opens up future growth space 最新动态 ➢ 做大成熟医药业务，大力投入新方向的开发。2025 年以来，公司在医药产品技术研发方面持续发力，从传统小 分子药物拓展到氨基酸、多肽、PROTAC/ADC 连接子、寡核苷酸等。团队通过持续开发、加速赋能客户的早期 临床项目转化，为客户提供开发 ADC/PROTAC 药物所需的多样性 Linker 合成服务，并具备多肽，PEG 等类型 Linker 克级到百克级别的交付经验。同时，公司能够根据客户需求进行 Linker 的结构和合成路线的设计及优化。 这些新方向的尝试有望拓展公司医药 CDMO 业务的服务领域，帮助公司承接更多的项目。 ➢ 植保 ...

Core Viewpoint - Lianhua Technology's stock rose by 5.15% to 12.67 CNY per share, with a trading volume of 569 million CNY and a market capitalization of 11.401 billion CNY as of November 27 [1] Company Overview - Lianhua Technology Co., Ltd. is located in Taizhou, Zhejiang Province, established on September 14, 1998, and listed on June 19, 2008 [1] - The company operates in three main business segments: pesticides, pharmaceuticals, and functional chemicals [1] - Revenue composition: Pesticides 54.03%, Pharmaceuticals 32.32%, Functional Chemicals 8.42%, Equipment and Engineering Services 4.88%, Others 0.36% [1] Fund Holdings - One fund under China Merchants Fund holds a significant position in Lianhua Technology [2] - The fund, China Merchants CSI 2000 Index Enhanced A (019918), held 972,000 shares, accounting for 0.61% of the fund's net value, ranking as the eighth largest holding [2] - The fund has generated a floating profit of approximately 602,600 CNY today [2] Fund Performance - China Merchants CSI 2000 Index Enhanced A (019918) has a total asset size of 573 million CNY and has achieved a year-to-date return of 42.91%, ranking 619 out of 4206 in its category [2] - Over the past year, the fund has returned 43.35%, ranking 630 out of 4006 [2] - Since inception, the fund has delivered a return of 64.92% [2]

证券之星消息，2025年11月27日联化科技（002250）发布公告称中金公司裘孝锋 李熹凌、中信保诚基金 姚思洲、财通证券宋田田、东方财富汪智谦 陈迪迪、南方基金陈哲、华富基金廖庆阳、华泰柏瑞丁志 远、森锦投资季亮、银华资产吴颖、East Capital陆宇熙于2025年11月26日调研我司。 具体内容如下： 问：公司医药业务发展迅速，后续情况如何，是否有引入新的客户？ 答：公司医药业务坚持大客户战略，以 CDMO 业务模式为主，公司已与多家全球领先医药企业达成合 作，同时公司积极拓展新客户，大力开拓潜在的战略型、高粘度客户。目前，公司医药事业部已与一批国 内外优质客户建立稳定商业联系，业务合作覆盖范围持续扩大，合作程度不断深入。公司跟随客户业务管 线布局公司产品管线，拓展公司技术能力，未来随着公司与客户业务的不断深入，客户专利期内产品的持 续推广，公司医药业务长期而言将有望实现增长。 问：公司医药业务研发有无在新的方向进行拓展？ 答：未来，公司将持续做大成熟业务，包括小分子 CDMO、起始原料及注册原料、GMP 中间体及高级原 料药；抓住小分子及小核酸业务 CDMO 的老客户新项目及新客户新项目；并大力投 ...

Group 1: Pharmaceutical Business Development - The company’s pharmaceutical business is rapidly developing, focusing on a major client strategy and CDMO business model, with partnerships established with several leading global pharmaceutical companies [1] - The pharmaceutical division has formed stable commercial relationships with a number of high-quality domestic and international clients, leading to an expansion of the business coverage and deepening cooperation [1] - Future growth in the pharmaceutical sector is anticipated as the company continues to promote products during clients' patent periods [1] Group 2: Research and Development Expansion - The company is expanding its R&D efforts into new areas, including small molecule CDMO, starting materials, GMP intermediates, and advanced raw materials [2] - New directions in R&D include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides, with a focus on providing diverse linker synthesis services for ADC/PROTAC drug development [2] - These initiatives are expected to broaden the service scope of the pharmaceutical CDMO business and enable the company to undertake more projects [2] Group 3: Key Product Updates - The company continues to provide advanced intermediates K amine for chlorantraniliprole under a long-term partnership with a client, with a stable pricing model based on cost-plus [3] - The company adheres to a long-term contract strategy, ensuring trust and integrity in client relationships [3] Group 4: New Energy Sector Outlook - The company primarily sells LiFSI and electrolyte products, with ongoing technical improvements in lithium hexafluorophosphate projects [4] - Revenue from the new energy business is expected to break through in 2025, with a focus on large client strategies and enhancing production capabilities [4] Group 5: Agricultural Protection Business - The agricultural protection industry is highly concentrated, with the company engaging in CDMO business driven by technological innovation and establishing long-term strategic partnerships with multiple international agricultural companies [6] - The company has multiple production bases in China and overseas, including a new base in Malaysia to meet supply chain needs [6] - The company aims to provide differentiated, one-stop supply chain solutions leveraging its comprehensive chemical supply chain in China and flexible production policies in the UK and Malaysia [6]

（文章来源：每日经济新闻） 联化科技（002250.SZ）11月24日在投资者互动平台表示，您好，公司根据客户要求的配方配置电解 液，其中如涉及LiFSI以自产为主，如涉及六氟磷酸锂以外购为主。谢谢！ 每经AI快讯，有投资者在投资者互动平台提问：请问贵司临海基地10万吨电解液是什么种类的电解 液？是否包含2万吨六氟磷酸锂和1万吨双氟磺亚酰胺锂？ ...

Core Viewpoint - The company is currently focused on the sales of LiFSI and electrolyte products, while the lithium hexafluorophosphate project is still in the technical improvement stage. The company's new energy business revenue is expected to achieve a breakthrough by 2025 [1] Group 1 - The company primarily sells LiFSI and electrolyte products [1] - The lithium hexafluorophosphate project is undergoing technical improvements [1] - The new energy business revenue is projected to significantly increase by 2025 [1]

格隆汇11月24日丨联化科技(002250.SZ)在投资者互动平台表示，公司目前以销售LiFSI和电解液产品为 主。 ...

Core Viewpoint - Lianhua Technology's stock has experienced significant fluctuations, with a year-to-date increase of 111.29% but a recent decline of 22.67% over the past five trading days [1] Group 1: Stock Performance - As of November 24, Lianhua Technology's stock price is 11.60 CNY per share, with a market capitalization of 10.439 billion CNY [1] - The stock has seen a trading volume of 2.68 billion CNY and a turnover rate of 2.53% [1] - The company has appeared on the "Dragon and Tiger List" 10 times this year, with the latest appearance on November 14, where it recorded a net purchase of 124 million CNY [1] Group 2: Business Overview - Lianhua Technology, established on September 14, 1998, and listed on June 19, 2008, operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals [2] - The revenue composition is as follows: pesticides 54.03%, pharmaceuticals 32.32%, functional chemicals 8.42%, equipment and engineering services 4.88%, and others 0.36% [2] - The company is categorized under the basic chemicals industry, specifically in agricultural chemical products [2] Group 3: Financial Performance - For the period from January to September 2025, Lianhua Technology achieved a revenue of 4.718 billion CNY, representing a year-on-year growth of 8.25% [2] - The net profit attributable to shareholders for the same period was 316 million CNY, showing a remarkable increase of 871.65% [2] - The company has distributed a total of 960 million CNY in dividends since its A-share listing, with 129 million CNY distributed in the last three years [3]